The Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California, United States of America.
The Center for Neural Science and Medicine, Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, California, United States of America.
PLoS Pathog. 2022 Aug 31;18(8):e1010350. doi: 10.1371/journal.ppat.1010350. eCollection 2022 Aug.
Host-pathogen dynamics are constantly at play during enteroviral infection. Coxsackievirus B (CVB) is a common juvenile enterovirus that infects multiple organs and drives inflammatory diseases including acute pancreatitis and myocarditis. Much like other enteroviruses, CVB is capable of manipulating host machinery to hijack and subvert autophagy for its benefit. We have previously reported that CVB triggers the release of infectious extracellular vesicles (EVs) which originate from autophagosomes. These EVs facilitate efficient dissemination of infectious virus. Here, we report that TBK1 (Tank-binding kinase 1) suppresses release of CVB-induced EVs. TBK1 is a multimeric kinase that directly activates autophagy adaptors for efficient cargo recruitment and induces type-1 interferons during viral-mediated STING recruitment. Positioning itself at the nexus of pathogen elimination, we hypothesized that loss of TBK1 could exacerbate CVB infection due to its specific role in autophagosome trafficking. Here we report that infection with CVB during genetic TBK1 knockdown significantly increases viral load and potentiates the bulk release of viral EVs. Similarly, suppressing TBK1 with small interfering RNA (siRNA) caused a marked increase in intracellular virus and EV release, while treatment in vivo with the TBK1-inhibitor Amlexanox exacerbated viral pancreatitis and EV spread. We further demonstrated that viral EV release is mediated by the autophagy modifier proteins GABARAPL1 and GABARAPL2 which facilitate autophagic flux. We observe that CVB infection stimulates autophagy and increases the release of GABARAPL1/2-positive EVs. We conclude that TBK1 plays additional antiviral roles by inducing autophagic flux during CVB infection independent of interferon signaling, and the loss of TBK1 better allows CVB-laden autophagosomes to circumvent lysosomal degradation, increasing the release of virus-laden EVs. This discovery sheds new light on the mechanisms involved in viral spread and EV propagation during acute enteroviral infection and highlights novel intracellular trafficking protein targets for antiviral therapy.
宿主-病原体动态在肠病毒感染过程中不断发挥作用。柯萨奇病毒 B(CVB)是一种常见的少年期肠道病毒,可感染多种器官,并引发包括急性胰腺炎和心肌炎在内的炎症性疾病。与其他肠道病毒一样,CVB 能够操纵宿主机制,劫持和颠覆自噬作用以谋取私利。我们之前曾报道过,CVB 会触发传染性细胞外囊泡(EVs)的释放,这些 EVs 源自自噬体。这些 EVs 有助于病毒的有效传播。在这里,我们报告 TBK1(Tank-binding kinase 1)可抑制由 CVB 诱导的 EVs 的释放。TBK1 是一种多聚体激酶,可直接激活自噬衔接蛋白,以有效募集货物,并在病毒介导的 STING 募集过程中诱导 I 型干扰素。由于其在病原体消除中的核心作用,我们假设 TBK1 的缺失可能会由于其在自噬体运输中的特定作用而使 CVB 感染恶化。在这里,我们报告说,在 TBK1 基因敲低的情况下感染 CVB 会显著增加病毒载量并促进大量病毒 EV 的释放。同样,用小干扰 RNA(siRNA)抑制 TBK1 会导致细胞内病毒和 EV 释放显著增加,而体内用 TBK1 抑制剂 Amlexanox 治疗会加剧病毒性胰腺炎和 EV 传播。我们进一步证明,病毒 EV 的释放是由自噬调节剂蛋白 GABARAPL1 和 GABARAPL2 介导的,它们促进自噬流。我们观察到,CVB 感染会刺激自噬并增加 GABARAPL1/2 阳性 EV 的释放。我们得出结论,TBK1 通过在 CVB 感染过程中诱导自噬流来发挥额外的抗病毒作用,而 TBK1 的缺失使载有 CVB 的自噬体更容易逃避溶酶体降解,从而增加了含病毒的 EV 的释放。这一发现为急性肠道病毒感染期间病毒传播和 EV 增殖的机制提供了新的认识,并突出了抗病毒治疗的新型细胞内运输蛋白靶标。